Stevanato Group (NYSE:STVN) reported a 19% increase in annual earnings on Wednesday, as the Italian drug containment specialist successfully leveraged a record mix of high-value products to offset persistent headwinds in its engineering segment.
The Piombino Dese-based company, a critical supplier to the global pharmaceutical and biotech industries, posted full-year 2025 revenue of €1.186 billion, representing 7% growth over the prior year.
The performance was largely underpinned by the company’s "high-value solutions"—a premium portfolio including specialized syringes and vials—which accounted for 46% of total revenue for the year and reached a record 49% in the fourth quarter.
This strategic shift helped drive a 160 basis-point expansion in the adjusted EBITDA margin to 25.1%.
Fourth-quarter revenue climbed 5% to €346.5 million, with gross profit margins reaching 30.9%.
The results reflect a successful transition toward higher-margin products like the Nexa platform, which is increasingly utilized for sensitive biologics and GLP-1 obesity treatments.